Results
1
Companies which are more than 50% undervalued based on analyst price target.
1 companies
Oryzon Genomics
Market Cap: €236.4m
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.
ORY
€2.88
7D
-3.1%
1Y
9.0%